Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis
← catalyst calendarNCT07271069 · readout in 224 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
150estimated
Sites
18
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-29 | actual | When the study began enrolling |
| Primary completion | 2027-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ulcerative Colitis (UC)
Interventions
- Drug: Ozanimod
- Drug: Azathioprine
Primary outcome
what the primary-completion date above is the date OFProportion of participants achieving steroid-free symptomatic remission
measured Week 12; Weeks 24 and 52
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed